Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma

HIDETAKA URAMOTO, TERUO IWATA, TAKAMITSU ONITSUKA, HIDEHIKO SHIMOKAWA, TAKESHI HANAGIRI and TSUNEHIRO OYAMA
Anticancer Research July 2010, 30 (7) 2513-2517;
HIDETAKA URAMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hidetaka@med.uoeh-u.ac.jp
TERUO IWATA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAMITSU ONITSUKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEHIKO SHIMOKAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI HANAGIRI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUNEHIRO OYAMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Representative IHC staining. A: Positive expression of E-cadherin with brown stained membranes of pre-treatment tumour in case 8. B: Positive expression of E-cadherin with brown stained membranes of post-treatment tumour is shown in case 8. C: Positive expression of gamma-catenin with brown stained cytoplasm of a pre-treatment tumour in case 1. D: Negative expression of gamma-catenin of post-treatment tumour in case 1. E: Negative expression of fibronectin of pre-treatment tumour in case 8. F: Positive expression of fibronectin with brown stained membrane of post-treatment tumour in case 8. G: Negative expression of vimentin of pre-treatment tumour in case 2. H: Positive expression of vimentin with brown stained membrane and cytoplasm of post-treatment tumour in case 2. Original magnification is ×100 in all cases.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    The mean proportion scores in a comparison between refractory and sensitive tumours are shown. Error bar: mean±standard deviation. S: Gefitinib-sensitive tumour, R: gefitinib-resistant tumour, E: E-cadherin, G: gamma-catenin, F: fibronectin, V: vimentin.

Tables

  • Figures
  • Table I.
  • Table II.
PreviousNext
Back to top

In this issue

Anticancer Research: 30 (7)
Anticancer Research
Vol. 30, Issue 7
July 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
13 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
HIDETAKA URAMOTO, TERUO IWATA, TAKAMITSU ONITSUKA, HIDEHIKO SHIMOKAWA, TAKESHI HANAGIRI, TSUNEHIRO OYAMA
Anticancer Research Jul 2010, 30 (7) 2513-2517;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
HIDETAKA URAMOTO, TERUO IWATA, TAKAMITSU ONITSUKA, HIDEHIKO SHIMOKAWA, TAKESHI HANAGIRI, TSUNEHIRO OYAMA
Anticancer Research Jul 2010, 30 (7) 2513-2517;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
  • Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
  • A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
  • Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer
  • CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
  • Engineering Multidimensional Evolutionary Forces to Combat Cancer
  • Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
  • Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition
  • The neuropilin 2 isoform NRP2b uniquely supports TGF{beta}-mediated progression in lung cancer
  • Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
  • Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
  • Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma
  • Gefitinib-mediated Reactive Oxygen Specie (ROS) Instigates Mitochondrial Dysfunction and Drug Resistance in Lung Cancer Cells
  • Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
  • A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
  • Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
  • Response to Erlotinib in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component
  • Prognostic Value of Aquired Resistance-related Molecules in Japanese Patients with NSCLC Treated with an EGFR-TKI
  • Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
  • Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes!
  • The Expression of CD146 Predicts a Poor Overall Survival in Patients with Adenocarcinoma of the Lung
  • The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma
  • Molecular Diagnosis of MACC1 Status in Lung Adenocarcinoma by Immunohistochemical Analysis
  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
  • Lack of Direct Association between EGFR Mutations and ER Beta Expression in Lung Cancer
  • Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung
  • Google Scholar

More in this TOC Section

  • TIG1 Inhibits the mTOR Signaling Pathway in Malignant Melanoma Through the VAC14 Protein
  • Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells
  • Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire